Zyversa Therapeutics將肥胖症及相關代謝併發症選擇爲炎症小體ASC抑制劑

快訊 · 07/25 19:57

Zyversa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome Asc Inhibitor Ic 100

Zyversa Therapeutics將肥胖症及相關代謝併發症選擇爲炎症小體ASC抑制劑IC100的主要指標。